Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OSTO:GUARD's PB Ratio is ranked better than 85.34% of 1228
companies
in the Biotechnology industry
Industry Median: 2.885
vs OSTO:GUARD: 0.87
During the past 12 months, Guard Therapeutics International AB's average Book Value Per Share Growth Rate was -59.40% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -50.80% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -40.60% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Guard Therapeutics International AB was 95.30% per year. The lowest was -62.20% per year. And the median was -33.60% per year.
Back to Basics: PB Ratio
Guard Therapeutics International AB (OSTO:GUARD) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Guard Therapeutics International AB PB Ratio Related Terms
Guard Therapeutics International AB PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guard Therapeutics International AB PB Ratio Chart
OSTO:GUARD vs VRTX, REGN, ALNY: PB Ratio Comparison
For the Biotechnology subindustry, Guard Therapeutics International AB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guard Therapeutics International AB PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Guard Therapeutics International AB's PB Ratio distribution charts can be found below:
* The bar in red indicates where Guard Therapeutics International AB's PB Ratio falls into.
Guard Therapeutics International AB PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Guard Therapeutics International AB (OSTO:GUARD) has a PB Ratio of 0.87 as of Jul. 14, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Guard Therapeutics International AB and its competitors. According to the industry distribution chart, Guard Therapeutics International AB ranks #180 out of 1228 companies in the Biotechnology industry, placing it in the top 14.7%.
Is Guard Therapeutics International AB's PB Ratio too high?
Guard Therapeutics International AB's current PB Ratio is 0.87. The Biotechnology industry median PB Ratio is 2.89. Guard Therapeutics International AB's value of 0.87 is 69.8% below this industry median. Based on the distribution chart, Guard Therapeutics International AB ranks #180 out of 1228 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Guard Therapeutics International AB has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Guard Therapeutics International AB's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Guard Therapeutics International AB ranks #180 out of 1228 companies for PB Ratio. This places Guard Therapeutics International AB in the top 15% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.89. Guard Therapeutics International AB's value of 0.87 is 69.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.89, based on 1,228 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Guard Therapeutics International AB's current PB Ratio of 0.87 is 69.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Guard Therapeutics International AB and its competitors. For the Biotechnology industry, the median PB Ratio is 2.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Guard Therapeutics International AB's current PB Ratio is 0.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guard Therapeutics International AB stock overvalued right now?
Guard Therapeutics International AB (OSTO:GUARD) has a current PB Ratio of 0.87. The current PB Ratio is 0.87 and 69.8% below the Biotechnology industry median of 2.89. Guard Therapeutics International AB's overall GF Score™ is 25/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Guard Therapeutics International AB (OSTO:GUARD), the current PB Ratio is 0.87 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Guard Therapeutics International AB Business Description
Guard Therapeutics International AB is engaged in developing and commercializing the lead drug candidate ROSgard, and thereby contribute to the better and less harmful treatment of acute kidney injuries.
25GF Score
Get the complete analysis for OSTO:GUARD
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:GUARD has been successfully added to your 
